Want to see KR:170900 full AI Analyst Report?
Dong-A ST Co., Ltd. (170900) Stock Price & Analysis
170900 Stock Chart & Stats
- Day’s Range
- $33,750.00 - $34,800.00
- 52-Week Range
- $31,600.00 - $56,380.95
- Previous Close
- $34,000.00
- Volume
- N/A
- Average Volume (3M)
- 6,810
- Market Cap
- KRW 322.72B
- Enterprise Value
- KRW 628.54B
- Total Cash (Recent Filing)
- KRW 213.24B
- Total Debt (Recent Filing)
- KRW 487.71B
- Price to Earnings (P/E)
- ―
- Beta
- 0.03
- Next Earnings
- Mar 24, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 10, 2026
- Dividend Yield
- 2.07%
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin
Steady revenue expansion combined with a solid gross margin indicates that Dong-A ST continues to generate demand while retaining meaningful value from its pharmaceutical products. This provides a constructive base for rebuilding profitability if operating execution remains consistent.
Improving Operating Profit
The reported improvement in operating profit is a favorable sign that earnings conversion and operating efficiency may be strengthening alongside sales growth. If sustained, better operating performance could improve earnings quality and support internally funded investment in the business.
Manageable Capitalization
Debt remains manageable for the sector and equity represents a meaningful share of capitalization, giving Dong-A ST a reasonable financial foundation. This supports continued investment in pharmaceutical operations while providing some capacity to absorb earnings volatility.
Bears Say
Persistent Cash Burn
Persistent negative free cash flow means reported business activity is not yet translating into sufficient cash generation. Continued cash consumption can increase reliance on funding or balance-sheet capacity, limiting flexibility for R&D, expansion, and other strategic priorities.
Weak Earnings Quality
Very low and volatile profitability weakens the durability of Dong-A ST’s earnings profile despite revenue growth and solid gross margins. Thin net income leaves limited protection against operating volatility and makes sustained returns from future sales expansion less certain.
Rising Leverage And Low Returns
Leverage has increased while returns on equity remain very low, indicating that additional capital has not yet translated into strong shareholder returns. This combination can constrain future capital allocation and heighten the importance of restoring consistent profitability.
Dong-A ST Co., Ltd. News
170900 FAQ
What was Dong-A ST Co., Ltd.’s price range in the past 12 months?
What is Dong-A ST Co., Ltd.’s market cap?
When is Dong-A ST Co., Ltd.’s upcoming earnings report date?
How were Dong-A ST Co., Ltd.’s earnings last quarter?
Is Dong-A ST Co., Ltd. overvalued?
Does Dong-A ST Co., Ltd. pay dividends?
What is Dong-A ST Co., Ltd.’s EPS estimate?
How many shares outstanding does Dong-A ST Co., Ltd. have?
What happened to Dong-A ST Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Dong-A ST Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Dong-A ST Co., Ltd.
Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various medical conditions, including tuberculosis (with treatments like Closerin and Terizidone), neutropenia in chemotherapy patients (such as Dulastin and Leucostim), and anemia stemming from chronic renal failure (Eporon). Its robust oncology offerings feature Gemcit for cancers affecting the lung, pancreas, breast, bladder, and ovaries; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; and Monotaxel, indicated for breast, prostate, head, neck, and gastric adenocarcinoma, among others. Additionally, Dong-A ST provides solutions for infertility and anovulation (Gonadopin), growth hormone deficiency and idiopathic short stature (Growtropin II), functional dyspepsia (Motilitone), gastritis (Stillen), diabetes (Suganon), and erectile dysfunction (Zydena). The company also actively participates in pharmaceutical licensing, encompassing both the acquisition and out-licensing of drugs. Its medical device segment includes advanced technological equipment, customized products, and specialized artificial cardiac circuit sets essential for complex open-heart surgeries. Dong-A ST Co., Ltd. was established in 1932 and is headquartered in Seoul, South Korea.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Jae-Hun Jung
- Employees
- 1,685
- Website
- www.donga-st.com
- Address
- 64 Cheonhodaero, Seoul, SL, 02587, KR
Dong-A ST Co., Ltd. (170900) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |

